Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...

Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or ...

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the standard 60-minute infusion of alteplase.

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...

Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application for Gazyva ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...